Transforming oncology with antibody therapeutics

Janssen EMEA Therapeutic Area Lead for Oncology discusses the potential of BsMAbs like amivantamab to address unmet needs in NSCLC treatment.

Related Keywords

Byoung Chul ,Martin Vogel ,Janssen Europe ,Personalized Medicine Coalition ,European Lung Cancer Congress ,Drug Administration ,Therapeutic Area Lead ,Therapeutic Area Lead Oncology ,Epidermal Growth Factor Receptor ,Mesenchymal Epithelial Transition Factor ,Bispecific Antibody ,Enable Multiple Mechanisms ,Broad Clinical ,Clinical Lung ,